An Observational Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung Cancer

Roche

Status: Completed

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT01488331

ML22973

Details and patient eligibility

About

This prospective, multi-center, observational study will assess the progression-free survival and safety of patients with locally advanced or metastatic non-small cell lung cancer treated with Tarceva (erlotinib) and not disease progressing after at least 9 months. Data will be collected for 24 months.

Enrollment: 217 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients, >/=18 years of age
• Diagnosis of locally advanced or metastatic non-small cell lung cancer (NSCLC, stage III/IV)
• Treatment with Tarceva monotherapy and not progressing after at least 9 months at the date of study start

Exclusion criteria

• Not agreeing to be followed-up (for a maximum of 24 months)

Trial design

217 participants in 1 patient group

Cohort